Presentation is loading. Please wait.

Presentation is loading. Please wait.

경희대학교병원 간암 다학제증례집담회 Multidisciplinary case conference Liver Cancer Conference 소화기 센터 회의실

Published byEdith Marshall Modified over 8 years ago

Similar presentations

Presentation on theme: "경희대학교병원 간암 다학제증례집담회 Multidisciplinary case conference Liver Cancer Conference 소화기 센터 회의실"— Presentation transcript:

1 경희대학교병원 간암 다학제증례집담회 Multidisciplinary case conference Liver Cancer Conference 소화기 센터 회의실 2013.03.15

2  98’ chronic hepatitis B  2000 Aplastic anemia  2007 BM transplantation  2013.2.19 Abdominal sono : HCC  2013.2.20 Liver CT : HCC (S7)  2013.2.22 PET CT : HCC (S7), No distant metastasis  2013.3.8 OP : Rt.hemihepatectomy ( c cholecystectomy)  토의 목적 : 치료 과정에 대한 review History Case 1 11648183 김 O 우 F/33 DM (-) HTN (-) Aplastic anemia s/p BMT (07’) Alcohol (-) / Smoking (-)

3 Underlying liver function and performance status CBC/DC WBC(mm 3 )9210 Hb(g/dl)12.2 PLT(mm 3 )166k PT(sec)15.2 INR1.22 Performance status: Grade 0 Chemistry TB/DB(mg/dL)1.06/- AST/ALT(IU/L)25/29 ALP/rGT(IU/L)97/39 Prot/Alb(g/dL)5.6/3.0 BUN/Cr(mg/dL)8/0.7 LC & Stage Child-Pugh- MELD score- Esophageal varices- Ascites- Encephalopathy- 11648183 김 O 우 F/33 Case 1 Tumor markers AFP (ng/mL)2.31 CEA (ng/mL) 0.262 PIVKA II (mAU/mL)- CA19-9 3.76 Viral markers/ underlying liver disease HBV / HCV(+/-) HBeAg / HBeAb(+/-) Virus titer>170.000.000 IU/mL Antiviral Tx(-) Alcohol(-)

4 Tumor Stage and Clinical Course 98’ 00’ 13.02 13.03.08 BMT Case 1 Aplastic anemia 11648183 김 O 우 F/33 CHB *Liver MR (2013.02.26) : Massive HCC at the posterior segment of the liver. A simple hepatic cyst at segment 5. Multiple small gallstones. PET (2013.2.22) High / Low uptakeHCC in segment 7 No abnormal hypermetabolic lesion suggesting distant metastasis OP Rt.hemihepatectomy HCC (S7) Abdominal sono Liver CT

5

6 Summary – 치료 방침 결정 11648183 김 O 우 F/33 Case 1 Current liver function Normal Well preserved (no risk of decompensation) Compensated (risk of decompensation) Decompensated Terminal state Extent of current tumor Localized (curative) Locally advanced (resectable) Locally advanced (unresectable) No < 4 Diffuse or multiple (> 3) Initial tumor stage Date: Modified UICC ( 대한간암연구학회 ) T 2, N 0, M 0 Stage: II BCLC Very early/Early/ Intermediate / Advanced Current status Locally advanced with Well preserved liver function Risk factors of recurrence / Tumor biology Extrahepatic metastasis N Tumor size > 5 cm, capsulation N Tumor number 1 Repeated TACE ( 1 회 / 기간 ) Y Vascular or bile duct invasion N High uptake of PET N High AFP or PIVKA II N Not normalized AFP after curative Tx N Histology (microvascular invasion) - Histology (satellite lesion, differentiation) - Poor control of underlying liver disease N

7 2002 년 B-viral LC 진단 후 2010 년부터 entecavir 복용 중. 2012.03.27 Liver CT :HCC (S8)  2012.04.05 TACE #1 시행 2012.07.09 Liver MR : viable HCC (S8)  2012.10.30 TACE #2 2012.10.15 Liver CT : r/o viable HCC  2012.12.12 Liver MR 시행. 2012.12.12 Liver MR : r/o viable HCC (S8,S5)  2013.01.09 TACE #3 2013.03.04 Liver MR : viable HCC (S8)  2013.03.13 TACE #4 향후 치료 방향 논의 History Case 2 10259334 조 O 복 F/57 DM/HTN/TBc/Hepatitis(-/+/-/+) B-viral LC : 2002 년 진단. entecavir 0.5mg Op Hx (-) Alcohol Hx (-), Smoking Hx (-)

8 Underlying liver function and performance status CBC/DC WBC(mm 3 )4940 Hb(g/dl)13.9 PLT(mm 3 )106k PT(sec)13.5 INR1.04 Performance status: Grade 0 Chemistry TB/DB(mg/dL)0.79/0.24 AST/ALT(IU/L)32/36 ALP/rGT(IU/L)79/36 Prot/Alb(g/dL)7.8/4.2 BUN/Cr(mg/dL)9/0.7 LC & Stage Child-PughA(5) MELD score2.56 Esophageal varices(-) Ascites- Encephalopathy- 10259334 조 O 복 F/57 Case 2 Tumor markers AFP (ng/mL)4.64 CEA (ng/mL) 1.98 PIVKA II (mAU/mL)- CA19-9 41.56 Viral markers/ underlying liver disease HBV / HCV(+/-) HBeAg / HBeAb(- / +) Virus titer<20 IU/mL Antiviral TxBENVRA 0.5 mg Alcohol(-)

9 2002 12.03 12.07 13.01 13.03 TACE #1 (2012.4.5) TACE #1 (2012.4.5) HCC (S8) *Liver MR (2013.03.04) : Recurred HCC at S8. Decreased size of hypovascular HCC at S5. Probably DN at the liver segment 3, 5 and 6. Lipiodolized HCC at S8, Underlying liver cirrhosis. 10259334 조 O 복 F/57 B-viral LC B-viral LC TACE #2 (2012.10.30) TACE #2 (2012.10.30) Viable HCC r/o Viable HCC TACE #3 (2013.01.09) TACE #3 (2013.01.09) Case 2 Tumor Stage and Clinical Course 10259334 조 O 복 F/57 HCC (S8) TACE #4 (2013.03.13) TACE #4 (2013.03.13) 12 년 03 월 12 년 05 월 12 년 008 월 12 년 10 월 12 년 12 월 13 년 3 월 AFP 4.503.812.753.133.314.64 PIVKA Ⅱ 1603105133--

10 Summary – 치료 방침 결정 10259334 조 O 복 F/57 Case 2 Current liver function Normal Well preserved (no risk of decompensation) Compensated (risk of decompensation) Decompensated Terminal state Extent of current tumor Localized (curative) Locally advanced (resectable) Locally advanced (unresectable) No < 4 Diffuse or multiple (> 3) Initial tumor stage Date: Modified UICC ( 대한간암연구학회 ) T 3, N 0, M 0 Stage: III BCLC Very early/Early/ Intermediate / Advanced Current status Locally advanced HCC with well preserved liver function and low-risk for recurrence Risk factors of recurrence / Tumor biology Extrahepatic metastasis N Tumor size > 5 cm, capsulation N Tumor number 2 Repeated TACE ( 2 회 / 기간 ) Y Vascular or bile duct invasion N High uptake of PET N High AFP or PIVKA II Y Not normalized AFP after curative Tx N Histology (microvascular invasion) - Histology (satellite lesion, differentiation) - Poor control of underlying liver disease -

11  2008 년 B-viral LC, entecavir 복용, 부산대 병원 f/u  2012.12.20 Abdomen CT : r/o HCC (S6)  2013.2.22 Liver MR : r/o early HCC (S6,S7)  토의 목적 : 향후 치료 방향 논의 History Case 3 12326543 황 O 길 M/61 DM (-) HTN (-) B-viral LC : child A, Entecavir 0.5 mg qd Alcohol (-) / Smoking (-)

12 Tumor Stage and Clinical Course 08 12.12 13.02 Case 3 Abdominal CT r/o HCC (S6) 12326543 황 O 길 M/61 B-viral LC *Liver MR (2013.02.22) : Three DNs at S7 and S6. R/O Early HCC (S7 nodule) Liver cirrhosis with esophageal varix and splenorenal shunt AP shunts Liver MR : R/O Early HCC (S6,S7) 2013.2.22 EGD Esophagus: Large esophageal varices (Cb F3 LS RC+) Stomach; No fundic varices Cardiac varices (Cb, F2, Lg-c, RC(-))

13 Summary – 치료 방침 결정 12326543 황 O 길 M/61 Case 3 Current liver function Normal Well preserved (no risk of decompensation) Compensated (risk of decompensation) Decompensated Terminal state Extent of current tumor Localized (curative) Locally advanced (resectable) Locally advanced (unresectable) No < 4 Diffuse or multiple (> 3) Initial tumor stage Date: Modified UICC ( 대한간암연구학회 ) T 2, N 0, M 0 Stage: II BCLC Very early/Early/ Intermediate / Advanced Risk factors of recurrence / Tumor biology Extrahepatic metastasis N Tumor size > 5 cm, capsulation N Tumor number 2 Repeated TACE ( 1 회 / 기간 ) Y Vascular or bile duct invasion N High uptake of PET N High AFP or PIVKA II N Not normalized AFP after curative Tx N Histology (microvascular invasion) - Histology (satellite lesion, differentiation) - Poor control of underlying liver disease N

14 99’ 위용종 (uncertain) 으로 subtotal gastrectomy 시행.(at 원자력병원 ). 내원 1 주일전부터 jaundice 증세 있어 본원 소화기 내과 외래 진료후 시행한 Abdominal US 에서 klatskin tumor 의심소견있어 F/E 위해 입원함. -2013.2.23 GB & Billiary CT : Klatskin tumor bismuth type IV -2013.2.25 ERCP : EST, Both IHD stent insertion -2013.2.26 Sono guided bx : Adenocarcinoma, metastatic -2013.2.26 PET CT : Suggestive of ascending colon cancer Multiple liver metastases -2013.3.8 Colonoscopy : Distal A-colon cancer - Bx Adenocarcinoma, moderately differentiated  토의 목적 : 향후 치료 방향 논의 History Case 4 12326091 김 O 준 M/52 DM/HTN/TBc/Hepatitis(-/-/-/-) OP Hx (-) Alcohol Hx (-), Smoking Hx (-)

15 Underlying liver function and performance status CBC/DC WBC(mm 3 )8020 Hb(g/dl)9.5 PLT(mm 3 )426k PT(sec)13.7 INR1.06 Performance status: Grade 0 Chemistry TB/DB(mg/dL)3.09/2.62 AST/ALT(IU/L)31/34 ALP/rGT(IU/L)94/98 Prot/Alb(g/dL)6.3/3.2 BUN/Cr(mg/dL)12/0.7 LC & Stage Child-Pugh- MELD score- Esophageal varices- Ascites- Encephalopathy- 12326091 김 O 준 M/52 Case 4 Tumor markers AFP (ng/mL)2.21 CEA (ng/mL) 5.94 PIVKA II (mAU/mL) - CA19-9 2.00 Viral markers/ underlying liver disease HBV / HCV(-/-) HBeAg / HBeAb(-/-) Virus titer - Antiviral Tx- Alcohol(-)

16 Tumor Stage and Clinical Course 2013.02.23 2013.02.25 2013.02.26 12321302 천 O 현 M/46 GB & Billiary CT Sono guided Bx : Adenocarcinoma, metastatic Sono guided Bx : Adenocarcinoma, metastatic PET CT ERCP : ENBD ERCP : ENBD Colonoscopy Bx : Adenocarcinoma, moderately differentiated Bx : Adenocarcinoma, moderately differentiated 2013.02.28 2013.03.08 2013.03.11 Cholangitis Chemo Tx : FOLFOX Case 4 12326091 김 O 준 M/52 PET (2013.01.22) Suggestive of ascending colon cancer Multiple liver metastases Metastatic lymphadenopathy in left paraaortic and aortocaval nodes MRCP (2013.02.25): Peribiliary metastasis at the confluence vs. Klatskin tumor (Bismuth type IV rather than IIIa). Multiple liver metastasis. Extensive porta hepatis and retroperitoneal LNs metastasis. ERCP : Both IHD Stent insertion ERCP : Both IHD Stent insertion MRCP

17 Summary – 치료 방침 결정 12326091 김 O 준 M/52 Case 4 Current liver function Normal Well preserved (no risk of decompensation) Compensated (risk of decompensation) Decompensated Terminal state Extent of current tumor Localized (curative) Locally advanced (resectable) Locally advanced (unresectable) No < 4 Diffuse or multiple (> 3) DX Klatskin tumor (Bismuth type IV ) c Colon cancer Colon cancer c biliary invasion, multiple liver meta Risk factors of recurrence / Tumor biology Extrahepatic metastasis N Tumor size > 5 cm, capsulation Y Tumor number >5 Repeated TACE (10 회 / 기간 ) Y Vascular or bile duct invasion N High uptake of PET N High AFP or PIVKA II N Not normalized AFP after curative Tx N Histology (microvascular invasion) - Histology (satellite lesion, differentiation) - Poor control of underlying liver disease N

18  2012.11 B-viral LC (at local)  2013.01.03 Liver CT : HCC (both lobe)  2013.01.04 Liver MR : HCC (both lobe)  2013.01.08 TACE #1  2013.03.06 Liver CT : aggravation of infiltrating HCC  토의 목적 : 향후 치료 방향 논의 History Case 5 12315259 안 O 진 M/36 DM (-) HTN (-) B-viral LC : Tenofovir Alcohol (+) : 1 년전 금주 / Smoking (+) 1 갑 x 20 년 Family Hx : 누나 - HBV carrier, 모 - 간경화로 사망, 부 - 폐암, COPD 로 사망

19 Underlying liver function and performance status CBC/DC WBC(mm 3 )7180 Hb(g/dl)16.1 PLT(mm 3 )172k PT(sec)16.4 INR1.34 Performance status: Grade 0 Chemistry TB/DB(mg/dL)3.2/1.9 AST/ALT(IU/L)178/23 ALP/rGT(IU/L)346/445 Prot/Alb(g/dL)7.3/3.5 BUN/Cr(mg/dL)9/0.7 LC & Stage Child-PughB(7) MELD score10.74 Esophageal varicesCb, F2-3, Lm, RC (+) AscitesGrade 2 Encephalopathy- 12315259 안 O 진 M/36 Case 5 Tumor markers AFP (ng/mL)303.2 CEA (ng/mL) 3.29 PIVKA II (mAU/mL)>75000 CA19-9 13.84 Viral markers/ underlying liver disease HBV / HCV(+/-) HBeAg / HBeAb(-/+) Virus titer 1960 IU/mL Antiviral TxTenofovir Alcohol(+)

20 Tumor Stage and Clinical Course 12.11 13.01 13.03 13.03.11 TACE #1 (2013.1.8) Case 5 HCC (Both lobe) 12315259 안 O 진 M/36 B-viral LC 13 년 01 월 13 년 03 월 AFP50.76303.2 PIVKA Ⅱ >75000 *Liver MR (2013.01.04) : Massive and diffuse infiltrating HCC involving both hepatic lobes. Tumor thrombosis in the right portal vein. PET (2013.01.07) High / Low uptakeDiffuse involvement of HCC, particularly right lobe. Liver MR : Aggravation of infiltrating HCC Sorafenib

21 Summary – 치료 방침 결정 12315259 안 O 진 M/36 Case 5 Current liver function Normal Well preserved (no risk of decompensation) Compensated (risk of decompensation) Decompensated Terminal state Extent of current tumor Localized (curative) Locally advanced (resectable) Locally advanced (unresectable) No < 4 Diffuse or multiple (> 3) Tumor stage Date: Modified UICC ( 대한간암연구학회 ) T 4, N 0, M 1 Stage: IV BCLC Very early/Early/ Intermediate / Advanced Current status Diffuse HCC with compensated liver function Risk factors of recurrence / Tumor biology Extrahepatic metastasis N Tumor size > 5 cm, capsulation N Tumor number >3 Repeated TACE ( 1 회 / 기간 ) Y Vascular or bile duct invasion N High uptake of PET Y High AFP or PIVKA II Y Not normalized AFP after curative Tx N Histology (microvascular invasion) - Histology (satellite lesion, differentiation) - Poor control of underlying liver disease N

Download ppt "경희대학교병원 간암 다학제증례집담회 Multidisciplinary case conference Liver Cancer Conference 소화기 센터 회의실"

Similar presentations

Intermediate stage HCC management

Intermediate stage HCC management
Staging Strategy and Treatment for Patients With HCC

Staging Strategy and Treatment for Patients With HCC
Great Debates & Updates in GI Malignancies

Great Debates & Updates in GI Malignancies
62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.

62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.
Ayman Abdo MD, AmBIM, FRCPC

Ayman Abdo MD, AmBIM, FRCPC
Tumors of the bile ducts

Tumors of the bile ducts
Biliary Tumors Cholangiocarcinoma and Cancer of the Gall Bladder

Biliary Tumors Cholangiocarcinoma and Cancer of the Gall Bladder
Epidemiology  Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer.  Worldwide, its prevalence follows that of hepatitis B.

Epidemiology  Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer.  Worldwide, its prevalence follows that of hepatitis B.
Cholestatic liver diseases:

Cholestatic liver diseases:
Guzman, Alexander Joseph Hipolito, April Lorraine

Guzman, Alexander Joseph Hipolito, April Lorraine
Case Report Patient PP Submitted by:Matthew Clower, MSIV Faculty:Sandra Oldham, MD Date:29 August 2007 Radiological Category:Principal Modality (1): Principal.

Case Report Patient PP Submitted by:Matthew Clower, MSIV Faculty:Sandra Oldham, MD Date:29 August 2007 Radiological Category:Principal Modality (1): Principal.
Gallbladder & bile duct Carcinoma Dr. m. h.khosravi.

Gallbladder & bile duct Carcinoma Dr. m. h.khosravi.
Mazen Hassanain. Bile duct Cancer Average age 60 years Ulcerative colitis is a common associated condition Subtypes: (1) periductal infiltrating, (2)

Mazen Hassanain. Bile duct Cancer Average age 60 years Ulcerative colitis is a common associated condition Subtypes: (1) periductal infiltrating, (2)
4 YEARS SURVIVAL OF 100 HCC PATIENTS TREATED WITH DC BEAD: A RETROSPECTIVE ANALYSIS Marta Burrel Vascular Interventional Unit Barcelona Clinic Liver Cancer.

4 YEARS SURVIVAL OF 100 HCC PATIENTS TREATED WITH DC BEAD: A RETROSPECTIVE ANALYSIS Marta Burrel Vascular Interventional Unit Barcelona Clinic Liver Cancer.
Diagnosing and Managing Cancers of the Liver and Bile Ducts Jeffrey S. Weinstein, MD Medical Director of Liver Transplantation Methodist Dallas Medical.

Diagnosing and Managing Cancers of the Liver and Bile Ducts Jeffrey S. Weinstein, MD Medical Director of Liver Transplantation Methodist Dallas Medical.
PANCREATIC CANCER.

PANCREATIC CANCER.
Hamid Tavakkoli, MD Associate Prof. of Gastroenterology.

Hamid Tavakkoli, MD Associate Prof. of Gastroenterology.
Painless Jaundice Randal Zhou M4. 58 yo asian man presents w  Jaundice x 2 months, upper abd discomfort, anorexia and pruritis  Physical: jaundiced,

Painless Jaundice Randal Zhou M4. 58 yo asian man presents w  Jaundice x 2 months, upper abd discomfort, anorexia and pruritis  Physical: jaundiced,
HCC Guidelines 2011 1.

HCC Guidelines
Hepatocellular Carcinoma from the ACC to Med E Paul M. Johnson Department of Internal Medicine University of North Carolina Hospitals February 12, 2010.

Hepatocellular Carcinoma from the ACC to Med E Paul M. Johnson Department of Internal Medicine University of North Carolina Hospitals February 12, 2010.

Similar presentations

Ads by Google